BUY TESTO-MED (400 MG/ML – 10 ML)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
Testo-Med 400 mg/ml – 10 ml is described in the supplied product information as an androgenic preparation for intramuscular administration containing three different esters of testosterone. The stated formulation combines testosterone cypionate, testosterone enanthate and testosterone propionate.
According to the supplied composition, the three active components are:
- Testosterone cypionate: 187 mg
- Testosterone enanthate: 188 mg
- Testosterone propionate: 25 mg
- Combined stated strength: 400 mg/ml
The product is presented as a 10 ml injectable preparation.
Product Specifications
- Product: Testo-Med
- Strength: 400 mg/ml
- Pack Size: 10 ml
- Testosterone cypionate: 187 mg
- Testosterone enanthate: 188 mg
- Testosterone propionate: 25 mg
- Dosage Form: Injectable
- Route: Intramuscular
- Drug Class: Androgenic preparation
- Active substances: Testosterone esters
- Market Status: Not supplied
- Manufacturer: Not supplied
- Storage: Cool, dry place; protect from light
No molecular formula, molecular weight, CAS number, excipient list, batch information or marketing authorisation details were supplied for the complete Testo-Med formulation.
Pharmacological Class
Testo-Med contains testosterone esters, which belong to the androgen class of steroid hormones.
Testosterone is the principal endogenous androgen in males and plays an important role in the development and maintenance of male reproductive tissues and secondary sexual characteristics. Testosterone and its metabolites act through the androgen receptor, an intracellular receptor that regulates gene expression in androgen-responsive tissues.
The source describes testosterone in relation to protein synthesis and nitrogen balance. These are recognised aspects of androgen physiology, although individual clinical responses vary.
Testosterone Ester Combination
Testo-Med combines three testosterone esters with different ester structures:
Testosterone cypionate, testosterone enanthate and testosterone propionate.
Esterification changes the physicochemical properties of testosterone and influences the rate at which testosterone becomes available following intramuscular administration.
The combination therefore contains testosterone in three esterified forms within one preparation. The supplied information does not provide validated product-specific pharmacokinetic data showing the precise absorption or elimination characteristics of the complete Testo-Med formulation.
Testosterone and Androgen-Receptor Signalling
Testosterone exerts many of its biological effects through androgen receptors. Receptor activation influences gene transcription in tissues responsive to androgenic signalling.
Testosterone can also be converted by endogenous enzymes into metabolites such as dihydrotestosterone (DHT) and estradiol. These pathways contribute to some of the physiological effects associated with androgen therapy.
Because androgen receptors are found in numerous tissues, testosterone therapy can have systemic effects extending beyond skeletal muscle.
Protein Metabolism and Nitrogen Balance
The supplied information states that testosterone can promote the growth of muscle, bone and other tissues through effects on protein metabolism and nitrogen balance.
Androgens may increase protein anabolism and reduce protein catabolism. However, nitrogen balance is influenced by nutritional intake as well as hormonal status. The supplied source specifically associates improved nitrogen balance with adequate intake of calories and protein.
These mechanisms do not constitute a guarantee of muscle growth or changes in body composition.
Clinical Indications
The supplied source describes Testo-Med as an androgenic preparation used for testosterone replacement therapy in male hypogonadal disorders.
Examples listed in the source include:
- Following castration
- Eunuchoidism
- Hypopituitarism
The product information provided does not include a current country-specific regulatory authorisation or official Summary of Product Characteristics for Testo-Med. Therefore, these indications should be understood as the indications stated in the supplied source rather than as independently verified EU-wide approvals.
Androgen Replacement
Testosterone replacement therapy aims to restore testosterone availability in men with clinically established androgen deficiency where treatment is medically appropriate.
Treatment decisions normally require assessment of symptoms, medical history and laboratory measurements. The choice of testosterone preparation and dosing schedule depends on the individual patient and the specific authorised product.
Testo-Med should therefore not be promoted for general energy enhancement, bodybuilding or performance improvement without an appropriate medical indication.
Cardiovascular and Fluid-Retention Considerations
The supplied information warns that androgen therapy may occasionally cause salt and fluid retention.
Patients with latent or overt:
- Cardiac failure
- Renal dysfunction
- Hypertension
- Epilepsy
- Migraine
should be appropriately monitored when receiving androgen treatment.
Middle-aged and elderly men with angina pectoris or serious circulatory disease require particularly careful medical supervision according to the supplied source.
Effects in Children
The source advises particular caution when androgens are used in prepubertal boys.
Exogenous androgen exposure can accelerate sexual development and may cause premature closure of the epiphyseal growth plates, potentially affecting final height.
The supplied source therefore states that androgen use should be approached cautiously in children and that Testo-Med is not recommended for children.
Reproductive Effects
The supplied source identifies several possible reproductive effects associated with androgen therapy, including:
- Priapism
- Excessive sexual stimulation
- Oligospermia
- Decreased ejaculatory volume
Exogenous testosterone can also suppress endogenous hormonal signalling through feedback mechanisms. This may affect the body’s own testosterone production and reproductive function.
Adverse Reactions
The supplied information identifies androgen-associated adverse effects including excessive sexual stimulation and priapism.
In prepubertal boys, possible effects include:
- Precocious sexual development
- Increased frequency of erections
- Phallic enlargement
- Premature epiphyseal closure
The source also identifies:
- Oligospermia
- Reduced ejaculatory volume
Patients experiencing androgen-associated adverse reactions should seek medical advice.
Precautions
According to the supplied source, if an androgen-associated adverse reaction occurs, treatment should be interrupted and may be resumed at a lower dose after the symptoms have resolved, under appropriate medical supervision.
Patients with cardiovascular or renal conditions require additional monitoring because androgen therapy may contribute to fluid retention.
The source also mentions a reduction in protein-bound iodine (PBI). It describes this change as having no clinical significance.
Contraindications
The supplied information states that Testo-Med should not be used in patients with known or suspected mammary or prostatic carcinoma in males.
The source contains a contradictory sentence stating that the medicine is “intended for use in female patients.” This conflicts with the preceding description of male testosterone replacement therapy and is not interpreted as a valid indication.
Because of this internal inconsistency, the female-use statement should be verified against authoritative product documentation before publication.
Dosage and Administration
The supplied source states that dosage should be adjusted according to the individual patient’s response and provides a broad weekly amount.
Because the supplied dosing information is internally presented as a general range rather than a verified product-specific prescribing regimen, it should not be interpreted as a universal dose.
The product should be administered intramuscularly under appropriate medical supervision and according to the official prescribing information applicable to the specific formulation.
Patients should not independently alter the dose or frequency of testosterone administration.
Regulatory Information
The supplied material does not provide a marketing authorisation number, EU authorisation or national regulatory approval for Testo-Med.
Therefore, no claim is made that this specific formulation is authorised, prescription-only or legally saleable in every European country.
The regulatory status should be confirmed with the relevant national medicines authority and current manufacturer documentation.
Manufacturer Information
No manufacturer was supplied in the source material for Testo-Med.
Consequently, no company name has been invented.
Presentation
Testo-Med 400 mg/ml – 10 ml injectable preparation.
Stated composition:
- 187 mg testosterone cypionate
- 188 mg testosterone enanthate
- 25 mg testosterone propionate
Storage
The supplied information states:
Store in a cool, dry place. Protect from light.
No specific temperature range was provided.
Important Pharmaceutical Disclaimer
Testo-Med contains pharmacologically active testosterone esters. The information above is based on the product data supplied and does not replace official prescribing information or professional medical advice.
Testosterone replacement should be undertaken only when medically indicated and under appropriate professional supervision. The bodybuilding and performance-related uses associated with testosterone products should not be treated as established therapeutic indications.
